Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug, By End Use, By Region & Competition, 2021-2031F

The global market for Ankylosing Spondylitis therapeutics is projected to expand significantly, rising from USD 7.88 Billion in 2025 to USD 11.27 Billion by 2031, at a Compound Annual Growth Rate of 6.15%. This market includes various pharmaceutical treatments such as nonsteroidal anti-inflammatory drugs, biologics like TNF and IL inhibitors, and Janus kinase inhibitors, all aimed at reducing inflammation and preventing spinal fusion. Key factors fueling this growth include an increasing worldwide prevalence of autoimmune disorders and a growing elderly population more prone to chronic inflammatory conditions. Enhanced diagnostic capabilities and greater awareness among healthcare professionals further contribute by enabling earlier detection and intervention, consequently expanding the number of patients eligible for advanced drug therapies.

Despite this growth, a major obstacle to market expansion is the considerable financial strain linked to biologic therapies, which restricts patient access and pressures global healthcare reimbursement systems. The challenge is compounded by the existence of refractory disease, which complicates treatment approaches. As evidenced by data from the German Rabbit register presented in 2025 by the European Alliance of Associations for Rheumatology, roughly 8.5% of patients with axial spondyloarthritis were deemed challenging to manage even with standard care. This highlights the ongoing clinical difficulty in effectively treating patients who do not respond sufficiently to current therapeutic options.

Market Driver

A significant driver of market growth is the growing use of biologics and other targeted therapies. These advanced pharmacotherapies, such as Janus kinase inhibitors, provide superior effectiveness for patients who do not respond well to traditional nonsteroidal anti-inflammatory drugs. Major pharmaceutical companies are experiencing substantial revenue increases from these specialized product lines, reflecting a shift in clinical preference towards treatments that actively modify disease activity rather than just alleviating symptoms. For example, AbbVie reported in its 'Third-Quarter 2024 Financial Results' in October 2024 that Rinvoq's global net revenues reached 1.61 billion dollars, a 45.3 percent increase year-over-year, largely due to its success in indications like ankylosing spondylitis, demonstrating the rising importance of targeted oral therapies for chronic inflammation.

Further boosting market dynamics is a strong clinical development pipeline and the subsequent introduction of new therapeutic agents. Innovation is progressing beyond tumor necrosis factor inhibitors, moving towards more precise dual-action cytokines that target specific inflammatory pathways, as shown by the rapid commercial adoption of recently approved treatments. UCB's '2024 Half-Year Financial Report' in July 2024 indicated that net sales for the new bimekizumab reached 215 million Euros, underscoring the immediate market influence of next-generation biologics. Moreover, established therapies are also broadening their market presence; Novartis reported in 2024 that third-quarter sales for the interleukin inhibitor Cosentyx rose by 28 percent in constant currencies, confirming ongoing demand within the immunology sector.

Market Challenge

A primary obstacle to the growth of the ankylosing spondylitis therapeutics market is the significant economic strain related to managing the condition. Expensive biologic treatments exert considerable pressure on healthcare reimbursement systems, resulting in restrictive coverage policies and consequently limiting patient access to these high-value therapies. This financial burden is compounded by the wider costs of overall care and lost productivity, which further diminish resources that could otherwise be allocated to advanced pharmacotherapy.

The severe financial implications for health systems are evident, with the Canadian Spondyloarthritis Association estimating in 2025 an annual economic cost of $2.01 billion attributed to axial spondyloarthritis. Facing these escalating expenditures, payers and insurance providers often prioritize cost-containment strategies over the adoption of new, costly treatments. These economic limitations directly shrink the accessible patient base for premium drugs and slow down market revenue growth, ultimately hindering the sector from reaching its full commercial potential despite the clinical availability of effective treatments.

Market Trends

A key trend reshaping the market is the increasing availability of cost-effective biosimilars, which offer financially attractive alternatives to high-priced reference biologics. As patent exclusivity for major tumor necrosis factor inhibitors expires, healthcare systems and payers are actively favoring these more affordable options to manage the rising budgetary impact of chronic autoimmune care. This strategic shift is fueling rapid commercial adoption and enhancing patient access to biologic therapies that were previously unaffordable due to cost constraints. For instance, Sandoz's 'Sandoz Financial Report 2024' in March 2025 revealed that biosimilar net sales reached $2.9 billion, a 30 percent increase in constant currencies from the prior year, demonstrating robust demand for cost-efficient treatments such as Hyrimoz in critical markets.

Additionally, the integration of AI-driven diagnostic and development tools is transforming the speed and accuracy with which new ankylosing spondylitis therapeutics are discovered. Pharmaceutical companies are increasingly leveraging artificial intelligence to unravel intricate inflammatory pathways and refine the selection of lead drug candidates, thereby significantly reducing the typically long drug discovery period. This operational change is marked by considerable investments in partnerships with AI-native biotechnology firms, aimed at identifying novel therapeutic targets for autoimmune conditions. An example of this is Sanofi's partnership, reported by BioWorld in January 2026, a deal potentially worth $2.56 billion, to utilize an AI-driven platform for discovering new treatments for autoimmune and inflammatory diseases.

Key Market Players

• AbbVie Inc.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• UCB S.A.
• Sanofi S.A.
• Eli Lilly and Company
• Bristol-Myers Squibb Compan

Report Scope

In this report, the Global Ankylosing Spondylitis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ankylosing Spondylitis Therapeutics Market, By Drug

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia

Ankylosing Spondylitis Therapeutics Market, By End Use

• Hospitals
• Clinics
• Others

Ankylosing Spondylitis Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ankylosing Spondylitis Therapeutics Market.

Available Customizations:

Global Ankylosing Spondylitis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).